AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22286156 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant LV leads
Number of subjects: 85
Study 22286156 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant LV lead
Number of subjects: 85
Study 20622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein after exercise (PRO)
Number of subjects: 2
Study 20622139 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate after exercise (CHO)
Number of subjects: 2
Study 19112513 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg HA with aluminium hydroxide adjuvant (30 microg+Al)
Number of subjects: 240
Study 19112513 — intervention group
Group type: COMPARATOR
Intervention: 7.5 microg HA without adjuvant
Number of subjects: 240
Study 19112513 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg HA with aluminium hydroxide adjuvant (half dose)
Number of subjects: 240
Study 19112513 — intervention group
Group type: COMPARATOR
Intervention: 3.8 microg HA without adjuvant (half dose)
Number of subjects: 240
Study 11176812 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 302
Study 11176812 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 302
Study 10342944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefpodoxime
Number of subjects: 0
Study 10342944 — intervention group
Group type: COMPARATOR
Intervention: 10-day course of penicillin V
Number of subjects: 0
Study 10342944 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin + clavulanate
Number of subjects: 0
Study 10342944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime
Number of subjects: 0
Study 8199153 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone (BIO‐OSS) placement in periapical defects
Number of subjects: 0
Study 3239464 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 68
Study 3239464 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 68
Study 31159778 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP-P intervention (community-based health promotion sessions)
Number of subjects: 2600
Study 31159778 — intervention group
Group type: COMPARATOR
Intervention: Control group (random sample of community residents)
Number of subjects: 2600
Study 31159778 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP-P intervention
Number of subjects: 2600
Study 28141699 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 91
Study 28141699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 91
Study 26875271 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized reference model of sagittal curves and navigation templates of pedicle screw (trial group)
Number of subjects: 42
Study 26875271 — intervention group
Group type: COMPARATOR
Intervention: Traditional pedicle screw internal fixation by fluoroscopy assistant (control group)
Number of subjects: 42
Study 23193200 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb (TT) technique
Number of subjects: 22
Study 23193200 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-finger (TF) technique
Number of subjects: 22
Study 23193200 — intervention group
Group type: COMPARATOR
Intervention: Overall compliance for both techniques
Number of subjects: 22
Study 21738078 — intervention group
Group type: COMPARATOR
Intervention: Moderate to severe pelvic organ prolapse (any type)
Number of subjects: 1192
Study 21738078 — intervention group
Group type: COMPARATOR
Intervention: Moderate to severe rectocele
Number of subjects: 1192
Study 18923027 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (to block central opioid function)
Number of subjects: 0
Study 16551761 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information exchange between social insurance physician and occupational physician.
Number of subjects: 1564
Study 16551761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured information exchange).
Number of subjects: 1564
Study 12667165 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI and tandospirone (T group)
Number of subjects: 36
Study 12667165 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI and diazepam (D group)
Number of subjects: 36
Study 12667165 — intervention group
Group type: COMPARATOR
Intervention: CMI alone (C group)
Number of subjects: 36
Study 12667165 — intervention group
Group type: EXPERIMENTAL
Intervention: T group
Number of subjects: 36
Study 10750252 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg once daily)
Number of subjects: 109
Study 10750252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 11322266 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine once daily (270 mg/m2/day)
Number of subjects: 53
Study 11322266 — intervention group
Group type: COMPARATOR
Intervention: Didanosine twice daily (270 mg/m2/day)
Number of subjects: 53
Study 11322266 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine once daily
Number of subjects: 53
Study 11322266 — intervention group
Group type: COMPARATOR
Intervention: Didanosine twice daily
Number of subjects: 53
Study 11322266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 53
Study 1556423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (2 L by nasal prongs)
Number of subjects: 94
Study 1556423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal prongs only)
Number of subjects: 94
Study 30982348 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 0
Study 30982348 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 0
Study 30982348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30020415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention to prevent serious fall injuries
Number of subjects: 5342
Study 30020415 — intervention group
Group type: COMPARATOR
Intervention: Central screening strategy (mail)
Number of subjects: 5342
Study 30020415 — intervention group
Group type: COMPARATOR
Intervention: Clinic screening strategy
Number of subjects: 5342
Study 26901519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Voluntary Counseling and Testing (MVCT)
Number of subjects: 0
Study 26901519 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Mobilization (CM)
Number of subjects: 0
Study 26901519 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Test Support Services (PTSS)
Number of subjects: 0
Study 24635120 — intervention group
Group type: EXPERIMENTAL
Intervention: VR graded exposure therapy (VR‐GET)
Number of subjects: 0
Study 21083769 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/day of Lippia citriodora extracts (PLX(®) -group)
Number of subjects: 15
Study 21083769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB-group)
Number of subjects: 15
Study 20637826 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective pressure impression technique
Number of subjects: 66
Study 20637826 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional pressure relief technique
Number of subjects: 66
Study 20637826 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 66
Study 18924048 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time NPO-group (STNPO-group) with unlimited intake of Pfrimmer Nutricia preOP up to 2 hours before surgery
Number of subjects: 42
Study 18924048 — intervention group
Group type: COMPARATOR
Intervention: Long-time NPO-group (LTNPO-group) with nothing per mouth after midnight
Number of subjects: 42
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of digoxin
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class IH-IV
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate in mL/min/1.73 m(2)
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary congestion by chest x-ray
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class III-IV
Number of subjects: 1926
Study 16858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ACE inhibitors
Number of subjects: 1926
Study 12963590 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment plus routine pediatric care
Number of subjects: 57
Study 12963590 — intervention group
Group type: COMPARATOR
Intervention: Routine pediatric care
Number of subjects: 57
Study 10394475 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (25 mg/day for 8 weeks)
Number of subjects: 44
Study 10394475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (693 mg/day for 8 weeks)
Number of subjects: 44
Study 8646956 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS; 60 cm)
Number of subjects: 680306
Study 8646956 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic polypectomy
Number of subjects: 680306
Study 8646956 — intervention group
Group type: COMPARATOR
Intervention: Double-contrast barium enema (DCE)
Number of subjects: 680306
Study 8646956 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 680306
Study 1643821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 110
Study 1643821 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 110
Study 6147549 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (8 large-volume exchanges over 4 weeks)
Number of subjects: 41
Study 6147549 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone only (0.3 mg/kg daily, increased weekly)
Number of subjects: 41
Study 6147549 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange group
Number of subjects: 41
Study 6147549 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone only group
Number of subjects: 41
Study 31449915 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 0
Study 31449915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 31449915 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR3 agonist
Number of subjects: 0
Study 31449915 — intervention group
Group type: COMPARATOR
Intervention: Cytokine treatment
Number of subjects: 0
Study 31449915 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy mucosal tissue)
Number of subjects: 0
Study 29553081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Lidocaine hydrochloride (LH) in rice nanogel
Number of subjects: 100
Study 29553081 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Lidocaine hydrochloride (LH) in rice nanogel
Number of subjects: 100
Study 29553081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Prilocaine hydrochloride (PH) in rice nanogel
Number of subjects: 100
Study 29553081 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Prilocaine hydrochloride (PH) in rice nanogel
Number of subjects: 100
Study 29553081 — intervention group
Group type: COMPARATOR
Intervention: RNG base (placebo)
Number of subjects: 100
Study 29553081 — intervention group
Group type: COMPARATOR
Intervention: Commercial anesthetic gels
Number of subjects: 100
Study 27036056 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Mindfulness Meditation Intervention (IMMI)
Number of subjects: 21
Study 27036056 — intervention group
Group type: COMPARATOR
Intervention: Internet-based health-and-wellness education program (control)
Number of subjects: 21
Study 27036056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 21
Study 24285122 — intervention group
Group type: EXPERIMENTAL
Intervention: CapsoCam capsule
Number of subjects: 73
Study 24285122 — intervention group
Group type: EXPERIMENTAL
Intervention: PillCam SB2
Number of subjects: 73
Study 24285122 — intervention group
Group type: COMPARATOR
Intervention: Both systems
Number of subjects: 73
Study 22263855 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation group (n=40)
Number of subjects: 81
Study 22263855 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 81
Study 19412831 — intervention group
Group type: EXPERIMENTAL
Intervention: 114 g SBC
Number of subjects: 20
Study 19412831 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g SBC with 144 g cooked paddy‐rice
Number of subjects: 20
Study 19412831 — intervention group
Group type: COMPARATOR
Intervention: 144 g cooked paddy‐rice
Number of subjects: 20
Study 17618137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (4 mg in the evenings for the first 2 postoperative days)
Number of subjects: 50
Study 17618137 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibiotic and anti-inflammatory medications only)
Number of subjects: 50
Study 17618137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 50
Study 17618137 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 15321438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (group O4, n = 23)
Number of subjects: 73
Study 15321438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg (group O8, n = 25)
Number of subjects: 73
Study 15321438 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (group P, n = 25)
Number of subjects: 73
Study 12243809 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, vinblastine, and mitomycin-C (later dropped) followed by surgery
Number of subjects: 75
Study 12243809 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, vinblastine (without mitomycin-C) followed by radiation therapy (RT)
Number of subjects: 75
Study 12243809 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy followed by surgery or RT
Number of subjects: 75
Study 12243809 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 75
Study 12243809 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT)
Number of subjects: 75
Study 12243809 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy only
Number of subjects: 75
Study 12243809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Number of subjects: 75
Study 12243809 — intervention group
Group type: COMPARATOR
Intervention: Surgery vs. RT
Number of subjects: 75
Study 9520189 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day contact lens (1-Day Acuvue)
Number of subjects: 16
Study 9520189 — intervention group
Group type: COMPARATOR
Intervention: 15-day contact lens (Acuvue)
Number of subjects: 16
Study 8126533 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure measurement using finger photoplethysmography
Number of subjects: 27
Study 8126533 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial blood pressure measurement
Number of subjects: 27
Study 2550402 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MK-906
Number of subjects: 12
Study 2550402 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MK-906
Number of subjects: 12
Study 1098721 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (mustine, vincristine, procarbazine, prednisone)
Number of subjects: 0
Study 1098721 — intervention group
Group type: COMPARATOR
Intervention: MOP (mustine, vincristine, procarbazine)
Number of subjects: 0
Study 31588904 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward lean condition
Number of subjects: 181
Study 31588904 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-disclosure condition
Number of subjects: 181
Study 31588904 — intervention group
Group type: COMPARATOR
Intervention: Voice pitch condition
Number of subjects: 181
Study 31588904 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 181
Study 28579236 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stent (BP-BES)
Number of subjects: 2707
Study 28579236 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (DP-EES)
Number of subjects: 2707
Study 25270679 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray
Number of subjects: 380
Study 23427960 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic cholecystectomy (SILC)
Number of subjects: 20
Study 23427960 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic cholecystectomy (LC)
Number of subjects: 20
Study 21956711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with pioglitazone (45 mg/day) and exenatide (10 μg twice daily) for 12 months
Number of subjects: 24
Study 21956711 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 24
Study 21956711 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-4 for 4 weeks in DIO mice
Number of subjects: 24
Study 19930832 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring analgesia and sedation
Number of subjects: 634
Study 19930832 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP >or= 60 mmHg
Number of subjects: 634
Study 19930832 — intervention group
Group type: EXPERIMENTAL
Intervention: BG >or= 80 mg/dl
Number of subjects: 634
Study 19930832 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia monitoring
Number of subjects: 634
Study 19930832 — intervention group
Group type: EXPERIMENTAL
Intervention: PIP <or= 35 cmH(2)O
Number of subjects: 634
Study 19930832 — intervention group
Group type: EXPERIMENTAL
Intervention: TV <or= 6 ml/kg
Number of subjects: 634
Study 19930832 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia monitoring, sedation monitoring, MAP >or= 60 mmHg, BG >or= 80 mg/dl and <or= 130 mg/dl, PIP <or= 35 cmH(2)O, TV <or= 6 ml/kg
Number of subjects: 634
Study 16496035 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 95
Study 12502992 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of local anesthetic and opioid (n = 34)
Number of subjects: 68
Study 12502992 — intervention group
Group type: COMPARATOR
Intervention: Usual care analgesic regimen (intramuscular meperidine, n = 34)
Number of subjects: 68
Study 10921442 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (local anaesthesia, sensory and procedural information, parental involvement)
Number of subjects: 31
Study 10921442 — intervention group
Group type: COMPARATOR
Intervention: No preparation (control group)
Number of subjects: 31
Study 8699777 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 20
Study 8699777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (+500 mg of metamizol)
Number of subjects: 20
Study 1355629 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 21
Study 1355629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6387207 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg nicotine chewing gum
Number of subjects: 205
Study 6387207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 31570004 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 0
Study 31570004 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 0
Study 31570004 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study 31277102 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao'er Feire Kechuan Oral Solution
Number of subjects: 30
Study 31277102 — intervention group
Group type: COMPARATOR
Intervention: Macrolide antibiotics (erythromycin and azithromycin)
Number of subjects: 30
Study 31277102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 30
Study 31277102 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 30
Study 28804935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 72
Study 28804935 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 72
Study 26330437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg plus Vitamin E 1000 IU
Number of subjects: 0
Study 23676961 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group A)
Number of subjects: 45
Study 23676961 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (Group B)
Number of subjects: 45
Study 23676961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of epidural and general anesthesia (Group C)
Number of subjects: 45
Study 21886816 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 80
Study 21886816 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 80
Study 17492378 — intervention group
Group type: EXPERIMENTAL
Intervention: CK19 mRNA positive status
Number of subjects: 195
Study 17492378 — intervention group
Group type: COMPARATOR
Intervention: CK19 mRNA negative status
Number of subjects: 195
Study 16606934 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (daily or biweekly injections)
Number of subjects: 30
Study 16606934 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients from another trial)
Number of subjects: 30
Study 12860359 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 24
Study 12860359 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 24
Study 11246616 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg orally) followed by octreotide (100 microg subcutaneously)
Number of subjects: 15
Study 11246616 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (100 microg subcutaneously)
Number of subjects: 15
Study 11246616 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg subcutaneously) in patients receiving beta-blockers
Number of subjects: 15
Study 11246616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after meal
Number of subjects: 15